Active substance Obinutuzumab
Holder Roche
Status Closed
Indication In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy
Public documents Approbation
Information for the patient
Informed consent
Last update 04/11/2015
Last updated on 04/11/2015